Ontology highlight
ABSTRACT:
SUBMITTER: Yokota K
PROVIDER: S-EPMC6916343 | biostudies-literature | 2019 Dec
REPOSITORIES: biostudies-literature
The Journal of dermatology 20191022 12
The multinational phase 3 CheckMate 238 trial compared adjuvant therapy with nivolumab versus ipilimumab among patients with resected stage III or IV melanoma (N = 906). In this Japanese subgroup analysis of CheckMate 238 (n = 28; nivolumab, n = 18; ipilimumab, n = 10), both the 12- and 18-month recurrence-free survival rates were 56% for nivolumab and 30% for ipilimumab (hazard ratio, 0.66; 97.56% confidence interval, 0.19-2.24; P = 0.4390). No new safety signals were reported for Japanese pati ...[more]